February 7, 2022
Life Sciences
  • The FDA will restart its domestic pharma-related surveillance inspections today after pausing the program in December. The agency has been stopping and starting since the COVID-19 pandemic began to “ensure the safety of its employees and those of the firms it regulates as the agency further adapts to the evolving COVID-19 pandemic and the spread of the omicron variant.” Last week, it determined that it would restart inspections as a result of the steep decline in COVID-19 cases across the country. (Article here; Press release here)